Year: 2016
The GMO Register Entry G0208-01 provides significant details of the clinical trial.
Year: 2016
All documentation submitted in respect of this notification was taken into consideration by the EPA inspector in his report to the Board of the Agency.
Year: 2016
Consent Conditions G0208-01 issued to BASF Plant Science GmbH, Germany for the deliberate release into the environment of GM potatoes with improved resistance to potato blight for purposes other than placing on the market i.e. to perform field trials, from April to October 2006 to 2010. This trial did not proceed.
Year: 2015
End-of-year 2012 report in accordance with EPA licence G0469-01
Year: 2014
An extract from the minutes of the EPA Board Meeting of 8 July 2014, at which The GUIDE Department's notification seeking consent to carry out a clinical trial at St James's Hospital, Dublin, was discussed.
Year: 2014
The GMO Register entry provides significant details of the clinical trial.
Year: 2014
All documentation submitted in respect of this notification was taken into consideration by the EPA Inspector in her report to the Board of the Agency.
Year: 2014
The GMO Register entry provides significant details of the veterinary trial
Year: 2014
Environmental Risk Assessment for Modified recombinant virus vaccine AdCh3NSmut1
Year: 2014
Newspaper Notice, Southside People, 16 April 2014
Year: 2014
Summary Notification Information Format (SNIF) for Modified recombinant virus vaccine AdCh3NSmut1
Year: 2014
Environmental Risk Assessment for Modified recombinant virus vaccine MVA-NSmut
Year: 2014
How to make a Representation to the EPA regarding Deliberate Release G0536-01
Year: 2014
Summary Notification Information Format (SNIF) for Modified recombinant virus vaccine MVA-NSmut
Year: 2014
G0536-01 Consent Conditions issued to The GUIDE Department, St. James's Hospital, Dublin on 22 July 2014 for a clinical trial using a Genetically Modified Organism (GMO)
Year: 2014
Environmental Risk Assessment for Modified recombinant virus vaccine MVA-NSmut
Year: 2014
Environmental Risk Assessment for Modified recombinant virus vaccine AdCh3NSmut1
